No Data
AnaptysBio Approves $75 Million Buyback Plan; Shares Rise
UBS Group: Raised the Target Price of HANSOH PHARMA to HKD 24, with management estimating that the contribution from Innovative Drugs will exceed 80%.
UBS Group released a Research Report stating that the Target Price for HANSOH PHARMA (03692) has been raised from HKD 22.1 to HKD 24, with a rating of "Buy." The bank also raised its earnings per share forecasts for the company by 11% and 9% for this year and next. The bank believes that key catalysts for HANSOH's stock price include the approval of auxiliary indications for Ameile in the first half of this year and GlaxoSmithKline launching a key study on HS-20093 (B7-H3) in the fourth quarter of this year. The report indicates that the contribution from the company's Innovative Drugs increased from 68% in 2023 to 77% last year, and this proportion is expected to exceed 80% this year, with Innovative Drug sales reaching.
23andMe Files for Bankruptcy, CEO and Co-founder Wojcicki Resigns
Barclays Remains a Hold on GlaxoSmithKline (GSK)
GSK's Application to Expand Use of Nucala (Mepolizumab) for the Treatment of COPD Accepted for Review by the European Medicines Agency
Democrats Warn Trump About Consequences of HIV Prevention Cuts
